Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

LaCroix, Bonnie L., Brendon M. Patierno, Bruce A. Sullenger, Daniel J. George, Steven R. Patierno, and Jennifer A. Freedman. “Nutritional profiling reveals glutamine-utilizing transaminases as a metabolic vulnerability of TAZ/YAP-driven breast cancer cells.” In Cancer Epidemiology Biomarkers & Prevention, 27:148–148. AMER ASSOC CANCER RESEARCH, 2018.

Scholars@Duke

George, Daniel J., Elisabeth I. Heath, A Oliver Sartor, Guru Sonpavde, William R. Berry, Patrick Healy, Carolyn Winters, et al. “Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).” In Journal of Clinical Oncology, Vol. 36. AMER SOC CLINICAL ONCOLOGY, 2018.

Scholars@Duke

Labriola, Matthew, Wen-Chi Foo, Daniel J. George, and Tian Zhang. “Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.” Clin Genitourin Cancer 16, no. 3 (June 2018): e509–12. https://doi.org/10.1016/j.clgc.2018.02.017.

PMID
29636282
Full Text

Batich, Kristen A., Janet S. Staats, Cliburn Chan, Cecile Krejsa, Daniel J. George, Kent J. Weinhold, and Tian Zhang. “Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).” In Journal of Clinical Oncology, 36:e16519–e16519. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.e16519.

Full Text

Slovin, Susan, William Clark, Joan Carles, Andrew Krivoshik, Jung Wook Park, Fong Wang, and Daniel George. “Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure: The UPWARD Study.” Jama Oncol 4, no. 5 (May 1, 2018): 702–6. https://doi.org/10.1001/jamaoncol.2017.3361.

PMID
29222530
Full Text

Choueiri, Toni K., Colin Hessel, Susan Halabi, Ben Sanford, M Dror Michaelson, Olwen Hahn, Meghara Walsh, et al. “Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.” Eur J Cancer 94 (May 2018): 115–25. https://doi.org/10.1016/j.ejca.2018.02.012.

PMID
29550566
Full Text

George, Daniel J., Jean-François Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Bernard Escudier, Paola Gerletti, et al. “Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.” Clin Cancer Res 24, no. 7 (April 1, 2018): 1554–61. https://doi.org/10.1158/1078-0432.CCR-17-2822.

PMID
29374054
Full Text

Humeniuk, Michael S., Rajan T. Gupta, Patrick Healy, Megan McNamara, Sundhar Ramalingam, Michael Harrison, Daniel George, Tian Zhang, Yuan Wu, and Andrew J. Armstrong. “Platinum sensitivity in metastatic prostate cancer: does histology matter?” Prostate Cancer Prostatic Dis 21, no. 1 (April 2018): 92–99. https://doi.org/10.1038/s41391-017-0017-6.

PMID
29230006
Full Text

Harshman, Lauren Christine, Maneka Puligandla, Naomi B. Haas, Mohamad Allaf, Charles G. Drake, David F. McDermott, Sabina Signoretti, et al. “A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).” In Journal of Clinical Oncology, 36:TPS710–TPS710. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.tps710.

Full Text

Zhu, Jason, Matthew D. Tucker, Patrick Healy, Michael Sandon Humeniuk, Casey Jarvis, Daniel J. George, and Andrew J. Armstrong. “Clinical utility of Foundation One tissue molecular profiling in men with metastatic prostate cancer.” In Journal of Clinical Oncology, 36:318–318. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.6_suppl.318.

Full Text

Pages